UK markets close in 7 hours 18 minutes

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
2.4450+0.0150 (+0.62%)
As of 09:52AM CEST. Market open.
Full screen
Previous close2.4300
Bid2.4350 x 0
Ask2.4450 x 0
Day's range2.4350 - 2.4950
52-week range1.7480 - 6.3400
Avg. volume376,845
Market cap487.535M
Beta (5Y monthly)0.81
PE ratio (TTM)N/A
EPS (TTM)-0.6280
Earnings date26 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

    Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established in vivo cancer modelEffects were shown to be T-cell-dependent and included a profound remodeling of the tumor microenvironment (TME), the formation of immune memory cells, and delivered results indicating the spread of the therapeutic effects into the periphery via the bloodstream and lymphoid organs

  • Globe Newswire

    Immunicum AB: Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

    Mendus Logo Mendus company logo Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirationsThe Company’s stock to continue trading under ticker symbol IMMU.ST on NASDAQ Sweden Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced that it has changed its corpo

  • Globe Newswire

    Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)

    Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on tumor recurrence and hard-to-treat established tumors, announced today that it has been granted an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST). This designation confirms the need and potential for ilixadencel as a new treatments for patients with GIST, which is a rare and difficult to treat subgroup of cance